Puma Biotechnology Inc (PBYI.OQ)
19 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|47||2011||Chairman of the Board, President, Chief Executive Officer|
|69||2011||Senior Vice President - Finance and Administration, Treasurer|
|59||2017||Chief Scientific Officer, Chief Medical Officer|
|50||2015||Chief Commercial Officer|
- BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America
- BRIEF-Puma Biotechnology Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines
- BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib
- BRIEF-Puma Biotechnology Inc Files For Non Timely 10-K - SEC Filing
- BRIEF-Puma Biotechnology Q4 Loss Per Share $1.71